A Deep Dive into the FDA Approval of NDA 215244 (s000): What We Know, What It Means, and What Comes Next
Introduction The issuance of label 215244s000 marks the formal U.S. FDA approval of a new therapeutic agent (or new indication) under NDA 215,244. While publicly available summaries are scarce, the full prescribing label document offers a wealth of technical information that can be unpacked to understand the drug’s mechanism, safety/efficacy profile, clinical trial evidence, potential […]
RYBREVANT (amivantamab-vmjw) 2025 Label: What Changed, Why It Matters, and How to Apply It in Practice
Bottom line: In early 2025 the RYBREVANT label tightened safety language (notably infusion-related reactions, anaphylaxis placement, and venous thromboembolism management with lazertinib) and clarified dosing/administration details. Later in 2025, FDA accepted a supplement to update overall survival results from MARIPOSA, which will flow into Clinical Studies once the updated PI posts. Together, these moves round […]
Breaking News: FDA Expands IZERVAY™ Label for Long-Term Use in Geographic Atrophy Management
1. What’s New? The U.S. Food and Drug Administration has approved an expanded prescribing label for IZERVAY™, enabling unlimited duration dosing in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) Astellas Pharma US, Inc. | News Room. Previously, treatment duration was capped at 12 months. 2. Clinical Evidence Behind the Expansion This […]
EMA CHMP Spotlight: July 21–24, 2025 Meeting Highlights
1. New Medicines Recommended for Approval The EMA’s Committee for Medicinal Products for Human Use (CHMP) reviewed promising therapies and issued positive opinions for 13 new medicines, including treatments targeting rare, life-threatening, or underserved conditions.European Medicines Agency (EMA) Notable approvals: 2. Biosimilars & Generics: Expanding Access The CHMP also issued positive opinions for four biosimilars […]